Landsec says London office rents rising quickly as it plots £2bn in sales
Unlock the Editor's Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Commercial landlord Land Securities says London office rents are rising quickly, with property valuations steady, as it prepares to sell £2bn of office blocks to fund a pivot into residential property.
The FTSE 100 landlord reported net rental income growth of 6.6 per cent in the year to March, on a like-for-like basis, across its £6.7bn central London portfolio of mostly City and West End offices.
'In London, office utilisation across our portfolio continues to grow,' Landsec chief executive Mark Allan said. 'In the near future, new supply across London is modest, so we expect our rental values this year to continue to grow at a broadly similar rate.'
Allan faces a daunting task to sell about £2bn of office blocks over five years to generate cash to buy and build thousands of homes, which he sees as a more attractive investment generating steady income. He said he expected these sales to start in 2026.
Office dealmaking remains at the lowest level since the global financial crisis, with very little liquidity for blocks worth more than £100mn. Deal volumes fell 18 per cent across Europe in the first quarter, according to data group MSCI, as a recovery in the wider commercial property transaction market stalled.
Investors have been wary of buying office buildings since the pandemic and the rise of hybrid working, while the post-Covid rise in interest rates slashed property values across the sector.
'Offices are in an investment market trading vacuum [above] £100mn, so portfolio valuations are more subjective,' Jefferies analyst Mike Prew said in a note ahead of Landsec's report. He warned that the pivot into residential 'could be slow to execute organically'.
Landsec share were down about 2 per cent in early London trading.
Allan cited recent joint venture deals by Norway's oil fund with Grosvenor and Shaftesbury Capital as examples of investors looking to 'acquire really scarce real estate in central London at a really attractive point in the cycle if you look at it on a long-term basis'.
Landsec said its £10.9bn portfolio, which also includes major shopping centres and a mix of other properties, increased in value by 1.1 per cent in the year to March, according to an independent valuation.
This continues a slow improvement in property values after a brutal two years during which prices fell about 25 per cent on average across Europe, according to Green Street analysts.
Allan is also making a big bet on the top tier of shopping centres — with large deals at Liverpool One and Bluewater last year. He argues these properties have strong demand from retailers but no new construction.
Landsec swung from a loss of £341mn in 2024 to a pre-tax profit of £393mn in 2025, driven by the rising property valuations.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Darden (NYSE:DRI) Reports Q2 In Line With Expectations
Restaurant company Darden (NYSE:DRI) met Wall Street's revenue expectations in Q2 CY2025, with sales up 10.6% year on year to $3.27 billion. Its GAAP profit of $2.58 per share was 12.1% below analysts' consensus estimates. Is now the time to buy Darden? Find out in our full research report. Revenue: $3.27 billion vs analyst estimates of $3.26 billion (10.6% year-on-year growth, in line) EPS (GAAP): $2.58 vs analyst expectations of $2.94 (12.1% miss) EPS (GAAP) guidance for the upcoming financial year 2026 is $10.60 at the midpoint, missing analyst estimates by 1.2% Operating Margin: 11.7%, down from 13.4% in the same quarter last year Free Cash Flow Margin: 8.4%, down from 9.7% in the same quarter last year Locations: 2,159 at quarter end, up from 2,031 in the same quarter last year Same-Store Sales rose 4.6% year on year (0% in the same quarter last year) Market Capitalization: $26.07 billion "We had a strong quarter with same-restaurant sales and earnings growth that exceeded our expectations," said Darden President & CEO Rick Cardenas. Founded in 1968 as Red Lobster, Darden (NYSE:DRI) is a leading American restaurant company that owns and operates a portfolio of popular restaurant brands. Examining a company's long-term performance can provide clues about its quality. Any business can experience short-term success, but top-performing ones enjoy sustained growth for years. With $12.08 billion in revenue over the past 12 months, Darden is one of the most widely recognized restaurant chains and benefits from customer loyalty, a luxury many don't have. Its scale also gives it negotiating leverage with suppliers, enabling it to source its ingredients at a lower cost. However, its scale is a double-edged sword because there is only so much real estate to build restaurants, placing a ceiling on its growth. For Darden to boost its sales, it likely needs to adjust its prices, launch new chains, or lean into foreign markets. As you can see below, Darden's sales grew at a mediocre 6% compounded annual growth rate over the last six years (we compare to 2019 to normalize for COVID-19 impacts) as it barely increased sales at existing, established dining locations. This quarter, Darden's year-on-year revenue growth was 10.6%, and its $3.27 billion of revenue was in line with Wall Street's estimates. Looking ahead, sell-side analysts expect revenue to grow 8.7% over the next 12 months, an acceleration versus the last six years. This projection is above average for the sector and indicates its newer menu offerings will catalyze better top-line performance. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Darden sported 2,159 locations in the latest quarter. Over the last two years, it has opened new restaurants at a rapid clip by averaging 6.1% annual growth, among the fastest in the restaurant sector. When a chain opens new restaurants, it usually means it's investing for growth because there's healthy demand for its meals and there are markets where its concepts have few or no locations. The change in a company's restaurant base only tells one side of the story. The other is the performance of its existing locations, which informs management teams whether they should expand or downsize their physical footprints. Same-store sales is an industry measure of whether revenue is growing at those existing restaurants and is driven by customer visits (often called traffic) and the average spending per customer (ticket). Darden's demand within its existing dining locations has been relatively stable over the last two years but was below most restaurant chains. On average, the company's same-store sales have grown by 1.7% per year. This performance suggests it should consider improving its foot traffic and efficiency before expanding its restaurant base. In the latest quarter, Darden's same-store sales rose 4.6% year on year. This growth was an acceleration from its historical levels, which is always an encouraging sign. We enjoyed seeing Darden beat analysts' same-store sales expectations this quarter. We were also happy its revenue was in line with Wall Street's estimates. On the other hand, its EPS fell short of Wall Street's estimates. Looking ahead, EPS guidance also came in below expectations. Overall, this was a weaker quarter. The stock remained flat at $221 immediately following the results. Darden didn't show it's best hand this quarter, but does that create an opportunity to buy the stock right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech
Shares of CureVac N.V. CVAC have skyrocketed 40.8% in a month after the company signed a definitive agreement to be acquired by BioNTech SE BNTX in an all-stock transaction last week. Per the agreement, each CVAC share will be exchanged for approximately $5.46 worth of BNTX American Depositary Shares (ADS), implying a total equity value of around $1.25 billion for CureVac. The consideration per ADS represents a premium of 55% to CVAC's three-month volume-weighted average price of approximately $3.53 as of June 11, 2025. Subject to the closing of the transaction, CureVac shareholders are expected to own between 4% and 6% of BioNTech. The closing of the transaction, expected in 2025, is based on the fulfillment of certain customary closing conditions and required regulatory approvals. Year to date, shares of CureVac have surged 61% against the industry's 4.8% decline. Image Source: Zacks Investment Research The acquisition of CureVac will help BioNTech enhance its capabilities in advancing investigational mRNA-based cancer immunotherapies by expanding its research, development, manufacturing and commercialization infrastructure. It complements BioNTech's existing strengths in mRNA design, delivery technologies and production. BNTX's Comirnaty is the first approved mRNA-based vaccine for COVID-19, which was developed in collaboration with Pfizer. Strategically, the deal will allow BioNTech to expand beyond its existing oncology pipeline and focus on its newer programs across several tumor types, including key assets like its mRNA-based cancer candidates and BNT327, a PD-L1xVEGF-A bispecific antibody. We remind the investors that earlier in June, BioNTech signed a strategic collaboration agreement with Bristol Myers BMY for the global co-development and co-commercialization of BNTX's BNT327, as monotherapy and in combinations, across numerous solid tumor types. BMY will pay $1.5 billion upfront, with $2 billion in additional payments through 2028 and up to $7.6 billion in milestones. BioNTech and Bristol Myers will equally share costs and profits. BNT327 is in late-stage, potentially registrational clinical studies for two different lung cancer indications. Another phase III study evaluating the candidate in triple-negative breast cancer is planned to start by the end of 2025. Early data show promising synergy in targeting two key cancer pathways. CureVac N.V. price-consensus-chart | CureVac N.V. Quote CureVac currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the biotech sector is Immunocore IMCR, currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. In the past 60 days, loss per share estimates for Immunocore's 2025 have improved from $1.50 to 86 cents. Loss per share estimates for 2026 have narrowed from $1.68 to $1.33 during the same period. IMCR stock has gained 7.5% year to date. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY) : Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX) : Free Stock Analysis Report CureVac N.V. (CVAC) : Free Stock Analysis Report Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
36 minutes ago
- Yahoo
Billionaire Chamath Palihapitiya hints at new SPAC despite community backlash
Billionaire Chamath Palihapitiya hints at new SPAC despite community backlash originally appeared on TheStreet. Billionaire investor and former Facebook executive Chamath Palihapitiya is one of the public figures from the traditional industry whose views are paid attention to by the crypto community. Recently, the billionaire hailed the public debut of Circle (NYSE: CRLC), the company behind the USDC stablecoin. He praised Circle for building the entire market structure for stablecoins early on. Palihapitiya, currently CEO at Social Capital, has launched a dozen special-purpose acquisition companies (SPACs). A SPAC is a publicly traded shell company formed with the purpose of acquiring or merging with a private company to take it public. The investor recently asked his X followers via a poll if he should launch another SPAC. But the X community is hardly supportive. Though his post has generated 2.4 million views so far, the response has been overwhelmingly negative. Not only did 71.3% of the responses say "No," the post even got a community note claiming that SPACs launched by Chamath during Covid years have generated "horrible returns," falling as much as 70% since their peaks. Regardless of the negative response, Palihapitiya wrote in the next X post that he received calls from many "Wall Street and Crypto Titans." He added: "I will probably do it." Palihapitiya said he will include the X poll and the community note in every SEC filing possible and hoped it will "maybe" go better this time. While nobody can tell if and when Palihapitiya will launch another SPAC, the crypto community was quick to jump in to trade opinions. Traders on Polymarket, the leading crypto-based prediction market, began to bet on him launching the company by Dec. 31, 2025. For now, the odds are sitting around 57% for "Yes," which means more than half of the Polymarket traders think Palihapitiya will launch a SPAC by the end of the year. Billionaire Chamath Palihapitiya hints at new SPAC despite community backlash first appeared on TheStreet on Jun 20, 2025 This story was originally reported by TheStreet on Jun 20, 2025, where it first appeared. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
